This randomized controlled study examined intubating conditions and haemodynamic changes following sevoflurane nitrous oxide induction in four groups: three different doses of alfentanil compared with low-dose alfentanil and suxamethonium. All patients received atropine 0.3 mg IV before induction of anaesthesia with vital capacity breaths of sevoflurane 8% (more than 7% in the inspiratory gas) in 60% nitrous oxide and oxygen. Patients were allocated randomly to four groups of intravenous supplements: group SA20, alfentanil 20 µg.kg -1 ; group SA25, alfentanil 25 µg.kg -1 ; group SA30, alfentanil 30 µg.kg -1 ; group SSA, alfentanil 10 µg.kg -1 and suxamethonium 1 mg.kg -1 . Orotracheal intubation and assessment of intubating conditions was performed by one of the investigators who was blinded to the subject's group. Intubating conditions were satisfactory or excellent in 83%, 80%, 92% and 96% of patients in groups SA20, SA25, SA30 and SSA respectively. These differences were not statistically significant. The increase in heart rate associated with laryngoscopy and tracheal intubation was effectively attenuated in all groups. Mean arterial pressure decreased significantly and similarly after induction in all groups. Two minutes after intubation the mean arterial pressure was increased significantly (P<0.05) compared to the post-induction value in group SSA. The intubating conditions obtained with sevoflurane plus alfentanil 30 µg.kg -1 were comparable to those provided by the sevoflurane, suxamethonium and alfentanil 10 µg.kg -1 combination.
Inhalational induction of anaesthesia using sevoflurane has been well described 1 . High concentrations of sevoflurane can be used for rapid induction due to its low blood gas solubility (0.69) 2 and minimal respiratory irritant effect 3 . Using vital capacity breaths of sevoflurane (7 to 8%) the speed of onset of induction is similar to that of an intravenous bolus of propofol. Sevoflurane with alfentanil provides better conditions for insertion of a laryngeal mask airway (LMA) than either sevoflurane alone or propofol with alfentanil 4. Satisfactory conditions for tracheal intubation without the use of muscle relaxant have been demonstrated after induction of anaesthesia with propofol and alfentanil 5, 6 , and in children, with sevoflurane alone 7 . This study of unpremedicated ASA 1 or 2 adults examines the effect of various doses of alfentanil on conditions for endotracheal intubation and haemodynamics after inhalational induction with sevoflurane without muscle relaxant compared with a group receiving sevoflurane, alfentanil and suxamethonium.
METHODS
The study was carried out on 100 unpremedicated adult ASA 1 or 2 patients aged between 18 and 65 years, scheduled for a variety of inpatient surgical procedures for which endotracheal intubation was the choice of anaesthetic technique. The hospital ethical committee and review board approved the study and informed consent was obtained from each patient. Smokers, patients with known or anticipated difficult intubation, those at risk of aspiration or adverse effects of coughing or straining, patients taking beta adrenergic blocking drugs, and those with an absolute contraindication to the use of sevoflurane, suxamethonium or alfentanil were excluded from the study.
The study was conducted in a randomized controlled fashion. All patients had a gaseous induction of anaesthesia with sevoflurane (7%) with 60% nitrous oxide in oxygen. The patients were randomly allocated to receive one of the following four intravenous supplements after induction: group SA20 received alfentanil 20 µg.kg -1 ; group SA25, alfentanil 25 µg.kg -1 ; group SA30, alfentanil 30 µg.kg -1 ; group SSA, alfentanil 10 µg.kg -1 and suxamethonium 1 mg.kg -1 . Sealed opaque envelopes assigning the patient to a group were opened by the investigator immediately before induction of anaesthesia. The patients were blind to the combination of induction drugs they would receive. Inhaled anaesthetic agents were delivered from a Narkomed-4 anaesthetic machine through a circle absorber system with a three litre reservoir bag. The breathing system was primed with the induction mixture until the inspired concentration of sevoflurane showed more than 7% on the vapour monitor. Patients were pre-oxygenated using a separate breathing system supplied from an auxiliary flow meter. An intravenous cannula was placed under local anaesthesia and all patients received IV atropine 0.3 mg and pre-oxygenation for three minutes. Patients were instructed to exhale maximally and then inhale maximally (vital capacity induction technique) a mixture consisting of 7% sevoflurane (8% on the vaporizer setting) and 60% nitrous oxide in oxygen, with a fresh gas flow of 6 l.min -1 . The patients were asked to hold the vital capacity breath for as long as possible. If necessary, a second and third breath were taken to achieve induction of anaesthesia. Once the patients lost their eyelash reflex, the concentration of sevoflurane was reduced to 5% on the vaporizer setting and the intravenous study drug(s) were administered over 30 seconds. Ventilation was assisted manually before intubation. Ninety seconds after administration of the study drug(s), one of the investigators, who was blinded to the group allocation, entered the operating room to perform direct laryngoscopy and orotracheal intubation and grade the quality of intubation. A modified form of the scoring system of Saarnivaara and Klemola 8 was used (Table 1) .
If intubation was unsuccessful after two attempts, patients who had not already received suxamethonium were given suxamethonium 1 mg.kg -1 . When this "rescue" suxamethonium was used, the intubation was classified as "failed" and the haemodynamic data was excluded from the results. Patients who were difficult to intubate after administration of suxamethonium were excluded. Non-invasive blood pressure, heart rate, and SpO 2 were monitored pre-induction, post-induction, and minutely for five minutes after intubation. End-tidal sevoflurane was monitored and recorded at the time of intubation. Once the tube position was confirmed, atracurium 0.5 mg.kg -1 was given and the patient's lungs were ventilated with 66% nitrous oxide in oxygen and sevoflurane (fraction end-tidal=1.5 to 2.0%). No further opioids were given till the required number of blood pressure and heart rate readings were taken. Further anaesthesia was according to the anaesthetist's preference. Twenty-four hours after anaesthesia, patients were asked about muscle pain and sore throat, which were graded none, slight, moderate or severe.
We performed a power analysis assuming that group SSA (suxamethonium) would have a 100% incidence of satisfactory or excellent intubating conditions (any patients with anticipated difficult intubations were to be excluded from the study). This was performed using a Z test (Sigma stat proportions power analysis, Jandel Scientific, San Rafael, California). This showed that 25 patients per group would give a 95% probability of detecting reduction in the proportion of patients having satisfactory or excellent intubation conditions from 100% in group SSA to 75% in other groups, and an 80% probability of detecting a reduction to 83% in other groups, with a P value of 0.05 in each case (i.e., β of 0.05 or 0.2, α of 0.05). Results are expressed as mean ±SD. Statistical analysis was performed using one-way ANOVA or paired t-test where appropriate, com- paring changes from preinduction values to postinduction and posttracheal intubation values within and between groups. Difference between groups for intubation scores were compared using a Z test for proportions (satisfactory or excellent versus poor or failed) and the Kruskal Wallis test. A P value of less than 0.05 was considered significant.
RESULTS
Each group consisted of 25 patients. One patient in group SA20 was excluded because of difficult intubation despite using rescue suxamethonium (thus n=99 patients analysed). There was no significant difference between the groups with respect to age, weight, sex and ASA grade distribution ( Table 2 ). There were no significant differences between the groups in time taken for the loss of eyelash reflex and end-tidal concentration of sevoflurane (%) at the time of intubation (Table 3) .
Rescue suxamethonium was required to facilitate intubation in three patients, one in each of groups SA20, SA25 and SA30. The patient in group SA30 received suxamethonium during positive pressure mask ventilation before any attempt to intubate the trachea, because of difficulty in ventilation probably caused by muscle rigidity and jaw tightness. Conditions for intubation in each group are summarized in Figure 1 . Intubation conditions were either satisfactory or excellent in twenty patients (83%) in group SA20 (P=0.306 v group SSA), 20 patients (80%) in group SA25 (P=0.192 v group SSA), 23 patients (92%) in group SA30 (P=1.0 v group SSA), and 24 patients (96%) in group SSA (Figure. 1 ).
There were no significant preinduction differences between groups in mean arterial pressure and heart rate ( Tables 4 and 5 ). Mean arterial pressure decreased significantly after induction in all the four groups. The magnitude of the decrease in mean arterial pressure with induction was not different between the groups. In group SSA a significant (P<0.05) rise in blood pressure, compared to earlier post-induction pressures, occurred at two minutes. There were no significant differences in heart rate between pre and post-induction and post-intubation values within any of the groups nor between the groups at any of the time intervals.
One (4%) patient in group SA20 and four (16%) patients in group SSA reported moderate to severe muscle pain. None of the patients in groups SA25 and SA30 reported any postoperative muscle pain. Twelve (50%) patients in group SA20, 13 Results are expressed as mean (SD). **P<0.01, comparing groups SA20, SA30 with group SSA; ***P<0.001, comparing groups SA20, SA25, SA30 with group SSA. (α denotes significant decrease (P<0.001) from preinduction value. β denotes significant increase (P<0.05) from postinduction value.
FIGURE 1:
The numbers of patient in each group with excellent, satisfactory, poor or failed intubating conditions. X, Y-axes denote groups and number of patients respectively. and eight (32%) patients in group SSA, reported moderate to severe postoperative sore throat.
DISCUSSION
The results of this study show that vital capacity inhalational induction with 7% sevoflurane and alfentanil 30 µg.kg -1 reliably provides excellent or satisfactory conditions for tracheal intubation in most (92%) unpremedicated ASA 1 or 2 adult patients. Simultaneous administration of suxamethonium with sevoflurane gas induction provides excellent or satisfactory conditions in 96% of patients. Although no statistical difference was found between our groups, based on the trend to better conditions in the SA30 group compared with the other non-relaxant groups and the lack of adverse effects of the higher doses of alfentanil, we would select the higher doses over the others for intubation without relaxant, in the conditions described.
The average time for acceptable tracheal intubating conditions after induction with three vital capacity breaths of 7% sevoflurane in 66% nitrous oxide and oxygen without alfentanil was 282 seconds 9 . Our results show that adding intravenous alfentanil 25 to 30 µg.kg -1 to this type of induction reduces the time to acceptable intubating conditions to approximately 165 seconds.
Several aspects of the design of this trial were based on findings from a preceding pilot trial. We found that a sevoflurane and alfentanil combination produced profound bradycardia in all patients, which required IV atropine to restore normal heart rate. Therefore, before the induction of anaesthesia, all patients in this trial were given 0.3 mg atropine IV which prevented bradycardia. The problem with bradycardia prompted us to exclude patients taking beta adrenergic antagonists. The pilot study also demonstrated a marked increase in heart rate and mean blood pressure following intubation after a sevoflurane and suxamethonium combination. To blunt the hypertensive response to intubation in the sevoflurane and suxamethonium group we added alfentanil 10 µg.kg -1 IV for this study.
Our haemodynamic findings were not unexpected. There was a significant increase in mean blood pressure at 2 minutes after tracheal intubation in the sevoflurane and suxamethonium combination compared to the pre-induction value, despite the 10 µg.kg -1 IV alfentanil which this group received. Mean arterial blood pressure (MAP) decreased significantly from the pre-induction values in all groups after induction of anaesthesia (approximately 20 mmHg reduction in MAP in all groups). Thwaites et al found that inhalational induction with sevoflurane 7% alone decreased the MAP by 10 mmHg 10 . The addition of the alfentanil has reduced the MAP by a further 10 mmHg (approximately) in our study. The increase in heart rate associated with laryngoscopy and tracheal intubation was effectively attenuated in all the four groups. The rise in blood pressure usually associated with intubation was not prevented in the group receiving sevoflurane, suxamethonium and alfentanil, probably due to the low dose (10 µg.kg -1 ) of alfentanil used in this group. Even in this group, blood pressure remained below the preinduction value at all times. Sevoflurane decreases mean arterial pressure predominantly through decreased peripheral resistance 11 . An in vitro study showed that a high concentration of sevoflurane caused myocardial depression, as a result of an effect on calcium channels 12 . Alfentanil may increase the haemodynamic effects of sevoflurane.
Alfentanil's antitussive and respiratory depressant effects make it a logical co-induction agent with sevoflurane for intubation. The patients were intubated 90 seconds after alfentanil was administered to match the onset of alfentanil's peak effect (60 to 90s). We did not administer alfentanil before the patients lost their eyelash reflex because it might interfere with the vital capacity induction Only 16% of patients who received suxamethonium experienced moderate to severe postoperative muscle pain. This incidence is much lower than that found in other studies. Muscle pains after suxamethonium may occur in up to 85% of patients 13 . Churchill-Davidson found that 66% of patients receiving suxamethonium experienced muscle pain 14 . Alcock et al found that 42% of patients experienced moderate to severe muscle pain after suxamethonium 15 . A possible explanation for the lower incidence of muscle pain in our study is the 10 µg.kg -1 of alfentanil administered along with suxamethonium during the induction of anaesthesia.
The incidence of postoperative sore throat varies 16 . In our groups SA30 and SSA we found 34% of patients had moderate to severe sore throat and more than 90% had satisfactory to excellent intubating conditions. In the other two groups in which only 80% of the patients had satisfactory to excellent intubating conditions, approximately 50% of patients experienced moderate to severe postoperative sore throat.
On the basis of this study, we believe that, following 0.3 mg of atropine IV, a sevoflurane vital capacity induction plus alfentanil 30 µg.kg -1 is a suitable technique for tracheal intubation without muscle relaxant in the majority of ASA 1 or 2 adult patients. Intubating conditions obtained with this combination were comparable to those provided by the sevoflurane, suxamethonium and alfentanil 10 µg.kg -1 combination.
